According to ARA Marketing Research and Consultancy, the Consumer Confidence Index (CCI) recorded an 8 points monthly drop to 77 points in August. The decline was due to the clashes that occurred between ... read more
The Lebanese Eurobonds market picked up slightly, where the BLOM Bond Index (BBI) gained 0.04% to 108.28 points. The 5Y and 10Y Lebanese Eurobonds’ yields lost 1 basis point (bp) each to settle at 5.06% ... read more
The Beirut Stock Exchange (BSE) kept trending down, where the BLOM Stock Index (BSI) lost 0.17% to reach 1,171.50 points. The real estate sector grasped a share of 36.30% with Solidere “A” and “B” shares ... read more
A multi-donor trust fund, the Lebanon Syrian Crisis Trust Fund (LSCTF), which is aimed at assisting Lebanese communities accommodating Syrian refugees, launched its first project on the 12th of September, ... read more
The Central Bank’s (BDL) balance sheet, revealed a 0.71% monthly rise in total assets to $85.26B by mid-September, mostly due to the 1.37% rise in its holding of foreign assets. Foreign assets (excluding ... read more
The Lebanese Eurobonds market weakened for the fifth day in a row, due to the decrease in demand for medium and long-term maturities. The BLOM Bond Index (BBI) fell by 0.10% to 108.24 points. The 5Y and ... read more
The Beirut Stock Exchange (BSE) remained on its downtrend, where the BLOM Stock Index (BSI) lost 0.21% to reach 1,171.50 points. The real estate sector grasped a share of 23.24% with Solidere “A” ... read more
The Lebanese Eurobonds market declined for the fourth day in a row, due to the decrease in demand for medium and long-term maturities. The BLOM Bond Index (BBI) fell by 0.06% to 108.35 points. The 5Y and ... read more
The Beirut Stock Exchange (BSE) started the week in the red, where the BLOM Stock Index (BSI) lost 0.31% to reach 1,174.89 points. The real estate sector grasped a share of 52.91%, with Solidere “A” and ... read more
Business Monitor International’s (BMI) report on Lebanon’s pharmaceuticals and healthcare reveals that Lebanon’s Pharmaceutical Risk/Reward Rating (RRR), for the fourth quarter (Q4) of 2014, stood at 53.9 ... read more
This website uses cookies in order to improve user experience. If you close this box or continue browsing, we will assume you agree with this. For more information click here